Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SON-1010 + Trabectedin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SON-1010 | SON 1010|SON1010 | SON-1010 is a recombinant variant of IL-12 linked to an albumin-binding domain, which potentially induces enhanced antitumor immune response (Cancer Res (2023) 83 (8_Supplement): CT245). | ||
| Trabectedin | Yondelis | ET-743 | Chemotherapy - Alkylating 18 | Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05352750 | Phase I | SON-1010 + Trabectedin SON-1010 | Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |